CA3010609A1 - Treatments and prevention of opioid neonatal abstinence syndrome - Google Patents
Treatments and prevention of opioid neonatal abstinence syndrome Download PDFInfo
- Publication number
- CA3010609A1 CA3010609A1 CA3010609A CA3010609A CA3010609A1 CA 3010609 A1 CA3010609 A1 CA 3010609A1 CA 3010609 A CA3010609 A CA 3010609A CA 3010609 A CA3010609 A CA 3010609A CA 3010609 A1 CA3010609 A1 CA 3010609A1
- Authority
- CA
- Canada
- Prior art keywords
- opioid
- fetal
- treatments
- prevention
- pregnant subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010013756 Drug withdrawal syndrome neonatal Diseases 0.000 title 1
- 208000002051 Neonatal Abstinence Syndrome Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 230000001605 fetal effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000003401 opiate antagonist Substances 0.000 abstract 3
- 208000026251 Opioid-Related disease Diseases 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 2
- 201000005040 opiate dependence Diseases 0.000 abstract 2
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002826 placenta Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276691P | 2016-01-08 | 2016-01-08 | |
| US62/276,691 | 2016-01-08 | ||
| PCT/US2017/012452 WO2017120417A1 (en) | 2016-01-08 | 2017-01-06 | Treatments and prevention of opioid neonatal abstinence syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3010609A1 true CA3010609A1 (en) | 2017-07-13 |
Family
ID=59274434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3010609A Pending CA3010609A1 (en) | 2016-01-08 | 2017-01-06 | Treatments and prevention of opioid neonatal abstinence syndrome |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10925870B2 (enExample) |
| EP (1) | EP3400066B1 (enExample) |
| JP (1) | JP7061568B2 (enExample) |
| CN (1) | CN108778423A (enExample) |
| AU (1) | AU2017206041B2 (enExample) |
| CA (1) | CA3010609A1 (enExample) |
| DK (1) | DK3400066T3 (enExample) |
| WO (1) | WO2017120417A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3066284A1 (en) * | 2018-04-09 | 2019-10-17 | Katana Pharmaceuticals, Inc. | Oxytocin compositions and methods of use |
| CA3124115A1 (en) * | 2019-01-04 | 2020-07-09 | Aether Therapeutics Inc. | Method for treating drug or alcohol dependency |
| US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| EP4366736A4 (en) * | 2021-07-06 | 2025-05-14 | Aether Therapeutics Inc. | LOW-DOSE NALTREXOL AND USES THEREOF |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE326222T1 (de) | 2000-03-15 | 2006-06-15 | Wolfgang Sadee | Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch |
| EA009921B1 (ru) * | 2003-07-25 | 2008-04-28 | Еуро-Селтик С.А. | Способ лечения синдрома отвыкания от зависимости у беременных женщин |
| MX2007005790A (es) | 2004-11-16 | 2007-09-11 | Limerick Neurosciences Inc | Metodos y composiciones para tratar el dolor. |
| US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
| CA2702680A1 (en) | 2007-10-18 | 2009-04-23 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
| WO2009079489A1 (en) * | 2007-12-17 | 2009-06-25 | The Ohio State University Research Foundation | Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof |
| US9226918B2 (en) * | 2008-12-04 | 2016-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating or preventing narcotic withdrawal symptoms |
-
2017
- 2017-01-06 US US16/068,593 patent/US10925870B2/en active Active
- 2017-01-06 JP JP2018535324A patent/JP7061568B2/ja active Active
- 2017-01-06 EP EP17736392.6A patent/EP3400066B1/en active Active
- 2017-01-06 CA CA3010609A patent/CA3010609A1/en active Pending
- 2017-01-06 CN CN201780015234.5A patent/CN108778423A/zh active Pending
- 2017-01-06 WO PCT/US2017/012452 patent/WO2017120417A1/en not_active Ceased
- 2017-01-06 DK DK17736392.6T patent/DK3400066T3/da active
- 2017-01-06 AU AU2017206041A patent/AU2017206041B2/en active Active
-
2021
- 2021-02-22 US US17/180,945 patent/US12161641B2/en active Active
-
2024
- 2024-12-06 US US18/972,105 patent/US20250177379A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210205296A1 (en) | 2021-07-08 |
| AU2017206041A1 (en) | 2018-07-26 |
| US12161641B2 (en) | 2024-12-10 |
| US20250177379A1 (en) | 2025-06-05 |
| EP3400066A1 (en) | 2018-11-14 |
| JP7061568B2 (ja) | 2022-04-28 |
| EP3400066A4 (en) | 2019-06-26 |
| JP2019501194A (ja) | 2019-01-17 |
| AU2017206041B2 (en) | 2022-07-28 |
| CN108778423A (zh) | 2018-11-09 |
| US10925870B2 (en) | 2021-02-23 |
| US20190015406A1 (en) | 2019-01-17 |
| NZ744112A (en) | 2025-05-30 |
| EP3400066B1 (en) | 2021-07-28 |
| DK3400066T3 (da) | 2021-10-18 |
| WO2017120417A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3010609A1 (en) | Treatments and prevention of opioid neonatal abstinence syndrome | |
| PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
| EP3207931A3 (en) | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies | |
| JP2016532722A5 (enExample) | ||
| HK1223319A1 (zh) | 用於治疗或预防眼科病的方法 | |
| SG10201901242PA (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| WO2014144075A8 (en) | Anticholinergic glycopyrrolate esters for the treatment of hyperhidrosis | |
| WO2014182643A3 (en) | Methods for treating hcv infection | |
| WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| HK1255481A1 (zh) | 用於治疗hcv的方法 | |
| JP2016520114A5 (enExample) | ||
| JP2019501194A5 (enExample) | ||
| WO2016178510A3 (ko) | 진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 | |
| HK1222585A1 (zh) | 用於提供疼痛减轻和麻醉的二氢埃托啡 | |
| WO2014107685A3 (en) | Compositions and methods for using huperzine and analogs thereof | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| WO2016122289A3 (ko) | 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물 | |
| WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| WO2017189906A8 (en) | Immune-based treatment of kras-variant cancer patients | |
| RU2014152196A (ru) | Способ улучшения функции печени | |
| IL312328A (en) | Treatment of irritability in patients on the autism spectrum with moderate to severe anxiety and/or social avoidance | |
| NZ744112B2 (en) | Treatments and prevention of opioid neonatal abstinence syndrome | |
| Talikoti et al. | Comparison of injection lignocaine (preservative free) 1.5 mg/kg iv with oral pregabalin 150 mg for attenuation haemodynamic response to laryngoscopy and tracheal intubation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211221 |
|
| EEER | Examination request |
Effective date: 20211221 |
|
| EEER | Examination request |
Effective date: 20211221 |
|
| EEER | Examination request |
Effective date: 20211221 |
|
| EEER | Examination request |
Effective date: 20211221 |
|
| EEER | Examination request |
Effective date: 20211221 |
|
| EEER | Examination request |
Effective date: 20211221 |
|
| EEER | Examination request |
Effective date: 20211221 |